TVTX Q2 2025 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$114M+111.5% YoY

Gross Profit

$113M98.7% margin

Operating Income

-$13M-11.1% margin

Net Income

-$13M-11.1% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+40.0%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$5M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$555M

Total Liabilities

$523M

Stockholders' Equity

$33M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$54M	+111.5%
Gross Profit	$113M	$42M	+170.7%
Operating Income	-$13M	-$67M	+81.1%
Net Income	-$13M	-$70M	+81.9%

Revenue Segments

License

$20M97%

Royalty

$600,0003%